{"disease":{"id":"colon-cancer-stage-iii","name":"colon cancer stage iii"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03958435","title":"Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07167147","title":"Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":7259,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT07143487","title":"Family Communications After Genetic Testing","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":4186,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT00096278","title":"Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2710,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07012538","title":"RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2640,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06924931","title":"Five-year Recurrence After LCME","phase":"","overall_status":"COMPLETED","enrollment_count":2529,"lead_sponsor_name":"Gødstrup Hospital","has_results":false},{"nct_id":"NCT01346280","title":"Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs","phase":"","overall_status":"COMPLETED","enrollment_count":1079,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02967289","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":792,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06490536","title":"The Sagittarius Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"IFOM ETS - The AIRC Institute of Molecular Oncology","has_results":false},{"nct_id":"NCT03516942","title":"Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT06108310","title":"ArTificial inTelligence-based RAdiogenomics in Colon Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT04342676","title":"Lymph Node Ratio and Kras Mutation in R Colon Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":433,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT06609551","title":"ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05179889","title":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":308,"lead_sponsor_name":"Chungnam National University Hospital","has_results":false},{"nct_id":"NCT03365882","title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03765736","title":"Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial","phase":"","overall_status":"TERMINATED","enrollment_count":199,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT07409844","title":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Ismail Gögenur","has_results":false},{"nct_id":"NCT06890624","title":"MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":138,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT02368886","title":"Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT07413146","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05308446","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02172651","title":"Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06746012","title":"Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04599140","title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04624555","title":"The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT04616183","title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04109924","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07140679","title":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04362839","title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04017650","title":"Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07405476","title":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03827044","title":"Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05870800","title":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT03317119","title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04123925","title":"Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT02381561","title":"Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02232152","title":"CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT02129218","title":"Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03992456","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT03781778","title":"Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03373188","title":"VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04164069","title":"Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Anne Noonan","has_results":false},{"nct_id":"NCT03592641","title":"Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03407716","title":"Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04044430","title":"Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05710406","title":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}